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Summary
Objective: We evaluated C-reactive protein (C-RP), a quantitative marker of the acute phase response, as a potential biomarker of prevalent
and incident osteoarthritis of the knee (OAK).
Methods: Serum C-reactive protein concentrations were characterized with ultrasensitive rate nephelometry in a population-based sample
of 1025 women (318 African-American and 707 Caucasian) who are enrollees in a study of musculoskeletal conditions at the mid-life.
Assignment of OAK was based on Kellgren-Lawrence (K–L) scores of 2 or more on radiographs. Prevalent OAK was based on the baseline
(1996) score while the classification of incident OAK was based on a score of 2 or greater at the follow-up examination 2.5 years later
amongst those with a baseline K–L scores of 0 or 1.
Results: At baseline, the prevalence of radiographic OAK was 12% in participants who were aged 27–53 years and 18% in the subgroup of
women aged 40–53 years. The mean C-RP value was 2.31 mg/L, with values ranging from below detection (0.3 mg/L) to 47.4 mg/L. Higher
C-RP concentrations were associated with both prevalent and incident OAK (P<0.0001, and P<0.0001, respectively). For each K–L score
increase from 0 to 3, there was a significantly higher mean C-RP value. Compared to women without incident OAK, women who developed
OAK in the 2.5-year follow-up had significantly higher baseline C-RP concentrations. Women with bilateral OAK had higher C-RP
concentrations than women with unilateral OAK (6.65 mg/L±0.56 vs 3.63 mg/L±0.42, P<0.007). BMI was highly correlated with C-RP
(r=0.58) and obesity was an effect modifier with respect to OAK and C-RP concentrations. When stratified according presence or absence
of OAK and obesity (BMI >30 kg/m2), mean C-RP values were: obesity and OAK, 6.3±0.4 mg/L; obesity but not OAK, 4.3 mg/L±0.2; no
obesity but OAK, 1.7 mg/L±0.8; and neither obesity nor OAK, 1.3 mg/L±0.2 mg/L. These stratum means were significantly different from
each other, indicating a higher C-RP with OAK after accounting for obesity.
Conclusion: C-RP, as a measure of an acute phase response and inflammation, is highly associated with OAK; however, its high correlation
with obesity limits its utility as an exclusive marker for OAK. © 2002 OsteoArthritis Research Society International. Published by Elsevier
Science Ltd. All rights reserved.
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Well-characterized biomarkers of osteoarthritis (OA) would
have several uses. First, the dissonance between painless
osteoarthritis of the knee (OAK), defined from radiographs,
and self-reported knee pain without radiographic evidence
of OAK is a clinical and epidemiological corundum whose
resolution could be more likely with the addition of a
sensitive or specific marker1–4. Second, there is a relative
absence of indicators for those processes leading to the
development of OA. Investigators acknowledge that by the
time joint changes are observed on X-ray, irreversible joint
damage may have already taken place. However, currently595there are no practical, reproducible, non-invasive, inexpen-
sive, or widely available methods to detect earlier articular
cartilage or subchondral bone loss in OA. Third, the impact
of interventions could be monitored more readily with
biomarkers other than X-rays.
We evaluated an ultrasensitive measure of C-reactive
protein (C-RP) as a marker for emergent radiographically-
defined knee OA and self-reported knee joint pain in a
population of African American and Caucasian mid-aged
women in Southeast Michigan. C-RP is an acute phase
response protein whose production is stimulated by
cytokines, particularly interleukin-6 (IL-6)5. While C-RP has
been related to the inflammatory activity of rheumatoid
arthritis, there has been little use of C-RP in clinical or
epidemiological studies of OA. It was commonly believed
that OA encompassed, at best, only a localized inflamma-
tory reaction even though arthroscopic studies of early
disease indicated histologic synovitis in approximately
half of those with cartilage damage6. At least three studies
have identified some association of C-RP and OA, though
usually in selected and small samples ascertained through
clinical services7–9.
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STUDY POPULATION
The sample used for this study included 1025 of the
1053 pre-and peri-menopausal women enrolled in the
Southeast Michigan Osteoarthritis Cohort for which there
were adequate blood samples. The cohort includes 543
women of the SWAN Study (Michigan Center) and 510
women of the Michigan Bone Health Study (MBHS) who
participated in the 1996 annual examination of both popu-
lations10. The SWAN Study at Michigan is a population-
based longitudinal study of African-American and
Caucasian women transitioning the mid-life and includes a
study of osteoarthritis as a site-specific study. The MBHS is
a population-based longitudinal study of musculo-
skeletal disease development in pre- and peri-menopausal
Caucasian women.
The SWAN group included 325 African American and
218 Caucasian women, aged 42–52 years in 1996, who
met eligibility criteria which included menstruation in the
3-month period prior to enrollment without the con-
temporary use of exogenous hormones. Potential adult
women enrollees were identified from households listed on
the billing records of the local electrical utility company.
Following enumeration of every household in the com-
munities of interest, women were recruited for the parent
SWAN study using telephone (40%) or face-to-face contact
with an interviewer11. OA studies were undertaken at the
1996 baseline examination, with a follow-up examination
2.5 years later.
The Michigan Bone Health Study (MBHS) sample of
women aged 28–48 years old (in 1996) was assembled
from two sampling frames. First, women were recruited
from the offspring listing of the historical Tecumseh
Community Health Study (TCHS) cohort that had been
organized in 1959–1960. Eighty percent of age-eligible
enrollees participated. The second frame was a community
census of women, also aged 28–48 years in 1996, who had
become community residents after the initial 1959–1960
family census. The first X-ray examination for osteoarthritis
in the MBHS population was conducted in 1992. Second
and third X-ray examinations for OA were conducted in
1996 and 1998, a time frame parallel with the SWAN OA
site-specific study.Measurements
Blood was drawn after an 8-h fast and on a day that was
in the 2–5 day window following the onset of menstrual
bleeding. More than 85% of enrollees had an early follicular
phase blood draw. Baseline (1996) blood samples were
available on 1025 of the 1053 members of the cohort. A
sample was not available on 28 women because partici-pants refused phlebotomy (N=6) or, because of a short
draw, there was insufficient volume. The blood sample was
chilled and centrifuged. The serum was aliquoted into
0.5 ml cyrovials, frozen, and then shipped on dry ice to the
Medical Research Laboratories. This Laboratory is certified
by the National Heart Lung and Blood Institute and Centers
for Disease Control Part III program.
C-reactive protein was measured using an ultra-
sensitive rate immunonephelometry methodology
(hs-C-RP on BN100, Dade-Behring, Marburg, Germany).
This method is based on light scattering agglutination of
C-reactive protein to polystyrene particles coated with
mouse monoclonal antibodies to C-RP. The sensitivity of
the assay (lowest detectable concentration) was 0.3 mg/L.
The mean intra-assay coefficient of variation (CV%) at
0.5 mg/L and 2.2 mg/L was 10–12% and 5–7%, respect-
ively. Glucose was measured using a hexokinase-coupled
reaction (Boehringer Mannheim Diagnostics, Indianapolis,
IN) and fasting values of 126 mg/dL were used as the cut
point for classification as diabetic.ARTHRITIS INFORMATION
Weight-bearing anteroposterior radiographs were taken
of both knees. Radiographs of both knees were evaluated
by at least two of the three authors (DJ, MH and MFS)
using the Kellgren–Lawrence system depicted in the Atlas
of Standard Radiographs of Arthritis12. Methods for
standardization and reading of the X-rays and agreement
statistics have been previously described10.
An arthritis questionnaire was administered to identify
pain and clinical characteristics, including current knee joint
pain and previous knee injury. To determine pain, partici-
pants were asked if they had any joint pain in their knees
during the previous month. Participants were also asked if
they had ever had a serious knee injury.OTHER MEASURES
Height (cm) and weight (kg) were measured using a
stadiometer and balance beam scale, respectively. Body
mass index (BMI) was calculated as weight (kg)/height
(m2). BMI was dichotomized at the median for the popula-
tion (BMI<30.0 kg/m2). Three blood pressure measure-
ments were taken using a standard mercury column when
seated and after a minimum of 5 min of rest and the latter
two measurements were averaged. Race/ethnicity was
categorized as African American or Caucasian based on
self-report. Smoking behavior was classified as current
smoker, ever smoked, or never smoked. Participants were
asked to bring both prescription and over-the-counter
preparations to the examination for recording by the inter-
viewer and, at time of interview, were asked about their
current medical health.Data analysis
Kellgren–Lawrence (K–L) scores were ranged from 0
and 4 and values greater than or equal to 2 were classified
as having OA. Prevalence of OA at the 1996 clinical
examination was calculated by using the number of women
with radiographically-defined OAK as the numerator and
the number of participants as the denominator. Incidence
was calculated by dividing the number of disease-free
women (by X-ray) in 1998 into the number of women whoWe addressed the following questions in a population-
based study of African American and Caucasian mid-aged
women. Are C-RP concentrations related to prevalent
radiographically-defined knee OA and do the concen-
trations increase with greater disease severity? Are higher
C-RP concentrations observed prior to identification of
newly recognized, radiographically-defined knee OA
(incident OA)? Are C-RP concentrations related to reports
of knee joint pain and knee injury? Are C-RP concen-
trations uniquely associated with OAK, after considering
alternative health-related conditions such as obesity?
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had developed in the 2.5-year follow-up period. These
measures were based on the individual women and not the
individual knee joint characteristics because C-RP concen-
trations are a systemic marker whose association with OAK
could not be attributed to a specific knee within a given
woman.
Chi-square tests were used to evaluate homogeneity of
categorical variable distributions (i.e., smoking, injury)
across OAK and pain groupings. C-RP values were trans-
formed with a natural logarithm for data analysis and
untransformed to report the C-RP original units (mg/L).
Analysis of variance (ANOVA) was used to estimate the
least square means (LS means) for continuous variables
(i.e., age, log C-RP, BMI) in relation to OAK and pain
classification groups. Correlation analysis and analysis of
covariance was used to evaluate obesity, diabetes, hyper-
tension, OAK classification and C-RP. Receiver operator
curve analysis was used to identify the cut points in theC-RP distribution where sensitivity and specificity would
be optimized for the use of C-RP data in clinical
decision-making.Results
The mean C-RP concentration was 2.31±0.11 mg/L in
this population of 1025 women whose mean age in 1996
was 42.9±0.1 years (Table I). The mean C-RP value in
African-American women was approximately 33% higher
than the mean value in Caucasian women (P<0.0001).
There was no significant association between mean C-RP
concentrations and 1996 smoking status (P=0.86) or age
(P=0.24).
The prevalence of OAK at the 1996 baseline was 12%
(N=122) in women aged 27–53 years and 18% among
women aged 40–53 years. The 2.5 year incidence between
1996 and 1998 was 3.2% (N=83) annually. The frequency
of self-reported knee pain and serious knee injury was 20%
and 18%, respectively, in 1996. At the 1998 follow-up, 31%
(N=253 women) reported knee joint pain.
There were higher mean C-RP concentrations in women
with prevalent OAK (4.82 mg/L±0.34 vs 2.09±0.12;
P<0.0001) and in women with incident OAK (4.31 mg/
L±0.36 vs 2.04±0.13; P<0.0001), as seen in Table II.
Higher mean concentrations of C-RP were found in women
who self-reported knee pain (P<0.0001) or who had knee
injury (P<0.0001).
Baseline C-RP concentrations increased in a progres-
sive manner with each interval of the Kellgren–Lawrence
scale for prevalent OAK (1996) or 1998 incident OA (see
Fig. 1). Women who were disease-free at the 1996 base-
line and who remained disease-free (i.e., a K–L score of 0
in 1998) had the lowest baseline C-RP concentrations (see
Table III). Women who were classified as disease-free in
1996 but had higher K–L scores in 1998 also had higher
baseline C-RP values. Further, there was progression in
C-RP values consistent with progression in K–L score.
Women with bilateral OAK had a higher mean C-RP
concentration than women with unilateral OAK (6.65 mg/
L±0.56 vs 3.63 mg/L±0.42, P<0.007).Table I
The mean and standard error or percentage and number of
selected characteristics among 1025 women aged 27–52 years:
Southeast Michigan Osteoarthritis Cohort
Overall
X±S.E. or % (N)
Number in the 1996 baseline 1025
Age (years) in 1996 42.9±0.1




OA of the Knee (Percent) number
1996 point prevalence (12%) 122
1996–1998 incidence (8%) 83
Current knee pain
In 1996 (20%) 204
In 1998 (31%) 253
Serious knee injury as of 1996 (18%) 180
Smoking status (1996)
never (55%) 562
past only (21%) 215
current (24%) 242
*Reported mean and Standard Error are the back transformed
values of log (CRP).
†Order of subtraction is 1998–1996.Table II
C-reactive protein concentrations (mg/L) and measures of the prevalence and incidence of osteoarthritis of the
knee (OAK), joint knee pain, and knee injury
C-reactive protein (mg/L) measured at baseline
LS mean±S.E. LS mean±S.E.
OAK (radiographic) with OAK without OAK
1996 point prevalence 4.82±0.34 2.09±0.12 <0.0001
1996–98 incidence 4.31±0.36 2.04±0.13 <0.0001
Current knee joint pain Pain No pain
in 1996 3.36±0.24 2.10±0.13 <0.0001
in 1998 3.16±0.22 1.92±0.16 <0.0001
Past knee injury reported at baseline Injury No injury
3.50±0.26 2.11±0.13 <0.0001
*P-value compares OAK to without OAK.C-RP, OAK, BMI, DIABETES AND HYPERTENSION
BMI was highly correlated with C-RP (r=0.58) and
obesity was an effect modifier with respect to OAK and
C-RP concentrations. As seen in Table IV, when stratified
according presence or absence of OAK and obesity (BMI
598 M. F. Sowers: CRP and knee osteoarthritis>30 kg/m2), mean C-RP values were: obesity and OAK,
6.3±0.4 mg/L; obesity but not OAK, 4.3 mg/L±0.2; no
obesity but OAK, 1.7 mg/L±0.8; and neither obesity nor
OAK, 1.3 mg/L±0.2 mg/L. These stratum means were sig-
nificantly different from each other, suggesting OAKaccounted for an elevation of C-RP concentration beyond
obesity.
C-RP concentrations have been related to cardiovascu-
lar disease and a question remains as to whether the C-RP
association with OAK is really a reflection of an underlying
cardiovascular co-morbidity. There is very little report of
diagnosed heart disease in this population; however,
15% of the population has hypertension when defined
by medications used, physician diagnosis, or two blood
pressure measurements whose average was greater
than 140/90 mmHg. Hypertension was not associated with
C-RP concentrations. Using a definition that included
medication use, physician diagnosis or fasting blood con-
centration greater than 126 mg/dl, 7.5% of the population
had diabetes and women with diabetes had higher C-RP
values. As shown in Table V, obese women with both OAK
and diabetes had a higher C-RP concentration than obese
non-diabetic women with OAK (10.1 mg/L±1.12 vs 5.6 mg/
L±0.5).
Using receiver operator curve (ROC) analysis in women
with a BMI less than 30 kg/m2, we identified that a C-RP cut
point of 4.1 mg/L had the highest sensitivity (Se=89%) but
markedly lower specificity (Sp=44%) for defining prevalent
and incident knee OA from radiographs. An optimal cut
point could not be identified for obese women, especially
those with diabetes.Fig. 1. (a) The association of C-RP measured in 1996 with
Kellgren–Lawrence scores ascertained in 1996. (b) The 1996
C-RP measures related to the Kellgren–Lawrence scores
observed in 1998.Table III
The 1996 C-reactive protein concentrations (mg/L) and baseline









0 (N=582) 0 (N=436) 1.59±0.22 <0.0001
1 (N=113) 2.39±0.32
2 (N=33) 4.16±0.56








*P-value—a value <0.05 indicates the likelihood that there is a
difference in the C-RP among the 1998 scores within each 1996
K–L score.Table IV
The interaction of BMI (kg/m2) and 1996 prevalent OAK or 1998






BMI≤30, no OAK 1.32±0.25*
BMI≤30, OAK 1.68±0.83†
BMI>30, no OAK 4.30±0.17‡
BMI>30, OAK 6.27±0.37
1998 incidence
BMI≤30, no OAK 1.28±0.27*
BMI≤30, OAK 2.67±0.62†
BMI>30, no OAK 4.36±0.17
BMI>30, OAK 5.36±0.41
*Significantly different than levels 2, 3, 4 (P<0.05).
†Significantly different than levels 1, 3, 4 (P<0.05).
‡Significantly different than level 4 (P<0.05).Discussion
We found that C-RP concentrations were higher in
prevalent and incident radiographically-defined cases of
knee OA in a large population-based study of African
American and Caucasian women. The C-RP concen-
trations increased with greater disease severity. C-RP
concentrations were higher in women with bilateral OAK
than women with unilateral OAK. Though C-RP concen-
trations were related to reports of knee joint pain and knee
injury, these relationships were not significant following
consideration of obesity.
Although OA is classified as a non-inflammatory disease,
others have evaluated synovial membranes and synovial
fluid and reported evidence of mild to moderate inflamma-
tion including morphological changes in the synovial mem-
brane6,13. Evidence suggests that the microheterogeneity
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C-RP concentrations according to body size, OAK and diabetes in a population-based sample of women:
Southeast Michigan Osteoarthritis Cohort














*Hypertension was not associated with C-RP.
†S.E.M. is Standard Error of the mean; LS means and S.E.M. have been back transformed.of acute phase glycoproteins in some patients with osteo-
arthritis is similar to those with rheumatoid arthritis and
other chronic inflammation14. Studies have recently
reported higher levels of interleukin-1 (IL-1), interleukin-6
(IL-6), and tumor necrosis  (TNF-) in the synovial fluid of
persons with knee OA15–19 and that greater cytokine
activity is involved with joint destruction5,20. At least two
cytokines, IL-1 and TNF-, are thought to induce the
synthesis and release of chondrocyte proteinases and
suppress chondrocyte synthesis of cartilage matrix
proteins21–29. IL-1 has been correlated with metallo-
protease activity in the synovial environment30,31 and
experimentally to stimulate the release of collagenase
and plasminogen activator from cartilage and synovial
cells32–34. Tumor necrosis factor  stimulates both IL-1 and
IL-6 activity35–37. Additionally, cytokines have been shown
to stimulate the liver to synthesize acute phase proteins,
including C-RP38. Thus, C-RP is considered an indirect
measure of cytokine activity27,39.
This work suggests that concurrent with the emergence
of radiographically-defined OA among these women, there
is an activation of the cytokine cascade. Limited literature
about inflammation in diabetes and cardiovascular disease
suggests that obesity is also associated with proinflamma-
tory cytokines including IL-637. IL-6 concentrations, in turn,
have been linked with reports of pain in various conditions
including herniated lumbar discs, ankylosing spondylitis,
and juvenile rheumatoid arthritis38–47. Further, it is known
that IL-6 concentrations decline following NSAID therapy46.
Thus, the constellation of obesity, pain, OAK and cytokine
production may be tightly linked and the role of obesity in
OA may involve a component that is mediated, in part,
through an immunological response.
We found that obesity was highly correlated with OAK
and C-RP concentrations and the three characteristics
were so interrelated that the additional and independent
contribution of OAK to C-RP was not sufficiently great
to recommend C-RP as a specific marker for OA.
Given recent reports of C-RP and cardiovascular disease
(CVD), one could question whether CVD in obese sub-
jects explained most of the C-RP effect. In this popu-
lation, hypertension was the most common CVD condition
for which we had data. Though hypertension was
related to obesity, it was not related to C-RP concen-
trations. In contrast, diabetes was highly related to C-RP
concentrations.
Our work confirms and extends that of others. Spector et
al.47 and Sharif et al.48 have identified that the average
C-RP concentration was approximately three times greateramong those with K–L scores of 2 or greater. We found that
the average C-RP concentrations were more than two
times greater among those with K–L scores of 2 or greater
as compared to women without radiographically-defined
disease. Conrozier et al. reported a similar differential with
respect to hip OA49.
We determined that among those women who were
disease free at baseline (a K–L score of 0 or 1), baseline
C-RP concentrations were significantly greater in those
whose disease would advance to a K–L score of 2 or
greater. Our finding that C-RP values were significantly
higher in women with both knees affected as compared to
women with one affected knee suggests an important
difference. Spector et al.47 identified that among those with
OA at the baseline, baseline C-RP concentrations were
greater in those whose disease had advanced at least one
K–L score at re-examination four years later. Collectively,
this suggests that knee OA is associated with elevated
C-RP and that there is an increase in mean C-RP con-
centration for each interval of the K–L scoring system.
Though we propose caution in using C-RP as a biomarker
attributable to just OA because of the concomitant inter-
relationships of OAK with obesity and diabetes, the
evidence is convincing that OA is an important contributor
to this chronic inflammatory environment.
In relating C-RP to progressively higher K–L scores,
there are at least two misconceptions that could arise. The
first misconception is that there should be a linear increase
in amount of C-RP in progressing from the osteophyte-
based K–L score of 2 as compared to the joint-space
narrowing and osteophytes in the K–L score of 3. This
progression may be driven by different underlying physi-
ology with different relations to the inflammatory processes.
The second misconception could arise in believing that the
X-ray, which is subject to numerous measurement errors
and incomplete visualization of knee surfaces, represents a
gold standard against which the predictability of C-RP
should be measured as a marker of disease. Table III
provides an example of the last misconception where it
indicates that K–L scores regressed from 2 to 0 in four
women while their C-RP concentrations remained higher.
Currently, it is not possible to define a C-RP concen-
tration that contributes to the definition of OA, though we
identified cut-points indicative of the sensitivity and specifi-
city of the measurement for predicting knee OA on radio-
graphs (K–L scoring) in leaner women. We reported that
the mean C-RP concentration for women who had preva-
lent OA was between 4–5 mg/L. Spector et al.47 reported
that the C-RP median for their population was 2.5 mg/L
600 M. F. Sowers: CRP and knee osteoarthritiswhile Wolfe49 identified that the mean C-RP in the clinical
population was 5.8 (IQR 2.5–12.5). This suggests that
there is a need to standardize assay methodologies and
frame the interpretation of C-RP considering the
co-occurrence of obesity and diabetes.
In summary, these results support the hypothesis that an
inflammatory component appears to be present prior to
classifying women with OA on the basis of X-ray changes.
The important correlations of C-RP with measures of
obesity suggest an opportunity for evaluation of metabolic
or immunological mechanisms as well as the mechanical
contribution of obesity to OA. C-RP is highly associated
with OAK; however, its high correlation with obesity limits
its utility as an exclusive biomarker for OAK.References
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